MX366046B - Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos. - Google Patents

Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos.

Info

Publication number
MX366046B
MX366046B MX2015016120A MX2015016120A MX366046B MX 366046 B MX366046 B MX 366046B MX 2015016120 A MX2015016120 A MX 2015016120A MX 2015016120 A MX2015016120 A MX 2015016120A MX 366046 B MX366046 B MX 366046B
Authority
MX
Mexico
Prior art keywords
binding molecules
complement factor
human complement
bind human
inflammatory disease
Prior art date
Application number
MX2015016120A
Other languages
English (en)
Spanish (es)
Other versions
MX2015016120A (es
Inventor
Johannes Simons Petrus
Boon Louis
Erik Hack Cornelis
Yildiz Cafer
Original Assignee
Broteio Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broteio Pharma B V filed Critical Broteio Pharma B V
Publication of MX2015016120A publication Critical patent/MX2015016120A/es
Publication of MX366046B publication Critical patent/MX366046B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015016120A 2013-05-23 2014-05-22 Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos. MX366046B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13168941 2013-05-23
PCT/NL2014/050327 WO2014189378A1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof

Publications (2)

Publication Number Publication Date
MX2015016120A MX2015016120A (es) 2016-10-28
MX366046B true MX366046B (es) 2019-06-26

Family

ID=48485015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016120A MX366046B (es) 2013-05-23 2014-05-22 Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos.

Country Status (14)

Country Link
US (2) US9944717B2 (https=)
EP (2) EP2999714B1 (https=)
JP (3) JP2016520313A (https=)
CN (1) CN105492461B (https=)
AU (1) AU2014269193C1 (https=)
CA (1) CA2913318C (https=)
DK (2) DK3725803T3 (https=)
ES (2) ES2904709T3 (https=)
HU (2) HUE049769T2 (https=)
LT (2) LT2999714T (https=)
MX (1) MX366046B (https=)
PL (2) PL3725803T3 (https=)
PT (2) PT3725803T (https=)
WO (1) WO2014189378A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CN105492461B (zh) * 2013-05-23 2019-11-26 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用
HUE073475T2 (hu) * 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
WO2020121282A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
GB2584105B (en) 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
WO2021026609A1 (en) * 2019-08-12 2021-02-18 CSL Innovation Pty Ltd Complement c2 binding proteins and uses thereof
AU2023210793A1 (en) * 2022-01-29 2024-06-06 Kira Pharmaceuticals (Suzhou) Ltd. Anti-c2 antibodies and uses thereof
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU2001249410A1 (en) 2000-03-23 2001-10-03 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
CN105492461B (zh) 2013-05-23 2019-11-26 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用

Also Published As

Publication number Publication date
JP2020007318A (ja) 2020-01-16
ES2904709T3 (es) 2022-04-05
LT2999714T (lt) 2020-07-10
HUE049769T2 (hu) 2020-10-28
US10717785B2 (en) 2020-07-21
AU2014269193C1 (en) 2020-02-20
US9944717B2 (en) 2018-04-17
DK2999714T3 (da) 2020-06-02
PL2999714T3 (pl) 2020-10-19
EP2999714B1 (en) 2020-04-01
US20180319895A1 (en) 2018-11-08
MX2015016120A (es) 2016-10-28
CN105492461A (zh) 2016-04-13
HUE057858T2 (hu) 2022-06-28
PT3725803T (pt) 2021-12-24
JP7414929B2 (ja) 2024-01-16
LT3725803T (lt) 2022-03-10
JP2016520313A (ja) 2016-07-14
CA2913318A1 (en) 2014-11-27
EP3725803A1 (en) 2020-10-21
AU2014269193A1 (en) 2015-12-17
JP2023002684A (ja) 2023-01-10
WO2014189378A1 (en) 2014-11-27
CA2913318C (en) 2024-03-26
AU2014269193B2 (en) 2019-08-15
ES2784616T3 (es) 2020-09-29
PT2999714T (pt) 2020-04-30
HK1223385A1 (zh) 2017-07-28
US20160108134A1 (en) 2016-04-21
EP3725803B1 (en) 2021-12-15
EP2999714A1 (en) 2016-03-30
CN105492461B (zh) 2019-11-26
DK3725803T3 (da) 2022-03-07
PL3725803T3 (pl) 2022-04-04
JP7163254B2 (ja) 2022-10-31

Similar Documents

Publication Publication Date Title
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2025009223A (es) Agentes de union a clec9a y su uso
CY1121097T1 (el) Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
WO2014190356A3 (en) Anti-b7-h5 antibodies and their uses
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
MY193649A (en) Bicyclic heterocycle compounds and their uses in therapy
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
WO2014151456A3 (en) Treatment of inflammatory diseases
PH12014501613A1 (en) Anti-asic1 antibodies and uses thereof
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
MX2014014443A (es) Agentes de ligacion a tlr3.
WO2015169811A3 (en) Anti-cxc chemokine receptor-2 binding molecules and uses thereof
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
GR1008177B (el) Μεθοδος επεξεργασιας φυτικων προϊοντων με βαση την ελατη για παραγωγη εκχυλισματος με βιολογικες δρασεις και χρηση του για τη θεραπεια νοσων στον ανθρωπο και στα ζωα.
HK1231933A1 (en) Aptamer construct

Legal Events

Date Code Title Description
FG Grant or registration